PMID- 11224487
OWN - NLM
STAT- MEDLINE
DCOM- 20010816
LR  - 20071115
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 86
IP  - 2
DP  - 2001 Feb
TI  - Sequential fluorescence in situ hybridization analyses for trisomy 12 in chronic 
      leukemic B-cell disorders.
PG  - 174-80
AB  - BACKGROUND AND OBJECTIVES: Trisomy 12 is one of the most common chromosomal 
      abnormalities in B-cell chronic lymphocytic leukemia (CLL). The aberration is 
      readily detected by fluorescence in situ hybridization (FISH). There are only a 
      few reports in which FISH analyses have been used to study the expansion of the 
      trisomy 12 clone over time. DESIGN AND METHODS: Repeat FISH analyses were 
      performed in 77 patients with a chronic leukemic B-cell disorder. The aim was to 
      study the development of the trisomy 12 clone throughout the course of the 
      disease, to measure the effect of therapy on the proportion of trisomic cells, 
      and to relate the findings to the response to therapy. RESULTS: Fifty-eight of 
      the 60 patients with no trisomy 12 at the initial test were consistently disomic 
      for chromosome 12, while 2 patients seemingly acquired trisomy 12 during 
      follow-up. Seventeen patients showed trisomy 12 at the first test. Expansion of 
      the trisomy 12 clone was seen in all patients with a progressive lymphocytosis. 
      In contrast to poor responders, patients responding well to chemotherapy showed a 
      significant decrease in the proportion of CD19+ cells with trisomy 12. The effect 
      of purine analogs in patients with trisomy 12 seemed inferior, both clinically 
      and when studying the effect on the trisomic clone. INTERPRETATIONS AND 
      CONCLUSIONS: There is a strong association between expansion of the trisomy 12 
      clone and progressive disease, both in treated and untreated patients. 
      Conversely, reduction of the trisomic B-cell clone was linked to clinical 
      response to chemotherapy. Acquisition of trisomy 12 remains a rare event.
FAU - Hjalmar, V
AU  - Hjalmar V
AD  - Division of Hematology, Karolinska Hospital, SE-171 76 Stockholm, Sweden. 
      viktoria.hjalmar@kids.ki.se
FAU - Hast, R
AU  - Hast R
FAU - Kimby, E
AU  - Kimby E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage
MH  - Chromosomes, Human, Pair 12/drug effects/*genetics
MH  - Clone Cells/drug effects/metabolism
MH  - Disease Progression
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics
MH  - Leukocytes, Mononuclear/drug effects/metabolism
MH  - Longitudinal Studies
MH  - Prospective Studies
MH  - Trisomy/*diagnosis
EDAT- 2001/02/27 10:00
MHDA- 2001/08/17 10:01
CRDT- 2001/02/27 10:00
PHST- 2001/02/27 10:00 [pubmed]
PHST- 2001/08/17 10:01 [medline]
PHST- 2001/02/27 10:00 [entrez]
PST - ppublish
SO  - Haematologica. 2001 Feb;86(2):174-80.